Back to the top of the range and above the 200 DMA again. Volume is the biggest since Oct. Not much not to like today. Setting the stage for the New Year. Hope everyone loaded the boat under 40 cents.
Stop with the tax selling nonsense. RGRX was and is not a big candidate for that. Those here waiting for a big tax loss pushdown to buy cheap shares are going to be waiting a very long time.
You can assume that recent 40 lowball inside offer today was the short. No long is going to put out an offer 3 cents below inside as stock is running higher. It was done to try and control stock and keep price in check. Thats been the mo all year. But, nice volume to take it out.
Will MM be able to continue this manipulation in the new year? Not a hard thing to do on this exchange with a penny stock that has little news. This however, is not going to last much longer. Important binary event upcoming in 1st Q with many other possible news items. Unless mm has some inside info that isnt even available about trial results, he had better be preparing an exit strategy.
All #'s will be tough to guess as netwolves is a mystery. But, i say glass 1/2 full now. To date in 3 Q's, we have done about 36 mil in total rev. Thats is already ahead of last years total(34mil).
Now, best of Q is coming in both netwolves and GEHC. I guess another 24 mil in total for netwolves and GEHC. Thats a record total rev right at 60 million in total rev. We about 1.3 million in 1 time expenses last year with the formation of IT and R&D. That should help some on the expense line with netwolves.
4 to 5 cent EPS
Vaso's stock price on 12/31/10 was .23. Will 2016 be any different? I think we will find out in the first Q of 2016 which way we are headed.
Happy New Year
Sentiment: Strong Buy
This again, from the severe Eye trial. The co primary endpoints on our upcoming DRY eye trial are "assesement of Total corneal staining and ocular discomfort. The key here is total, as all three areas of the cornea will be averaged to get the all important satistically significant #. When this # is hit, it will show what no other dry eye drug in the market has shown(or the FDA pending shire drug): The ability to heal. Whats that worth? RGRX maintains control of the entire EU market while the Koreans pay for trial.
The RGN-259-treated group had a 35.1% reduction of ocular discomfort compared to vehicle control (p=0.0141), and a 59.1% reduction of total corneal fluorescein staining compared to vehicle control (p=0.0108).
Merry Christmas and a very profitable New Year.
No, not a great idea if you want to go against Joe Edelman. He runs the No 1 bio fund this year (up 46% and 30% annulaized since 1999). Check NY post business today.
Also check his most recent filings, 9/30/15, and you will see he dumped 82% of his holding in irwd. While in the same filing, he started a new position in sgyp of 226,000 shares.
Do what you want, just another retail investor doing the wrong thing............Follow the money....and have a little conviction.
On an "off" day. Over 1000 of the jan 4 1/2 calls bought at .6
And a nice tick of 250 contracts of the march 3 calls at 1.9; right on the offer. Manipulation of equity can not hide the direction stock is headed in '16..........................much higher.
Published earlier but really points to success in the upcoming, much larger dry eye trial. Its a shame no one follows this stock. But, next trial result will change that:
The data demonstrated statistically significant improvements of corneal damage and ocular discomfort (signs and symptoms) in patients with severe dry eye, meeting the trial's key efficacy objectives. Moreover, improvements were seen at 28 days after cessation of treatment, supporting durability of the treatment. Other improvements seen in the trial included tear film breakup time and increased tear volume production. There were no adverse events
From the discussion section published in april of 2015 by Dr Sosne
A number of potential mechanisms may underlie these effects.3,4 Tβ4 has been shown to reduce production of inflammatory mediators and infiltration of inflammatory cells; these actions may reduce local concentrations of reactive oxygen species, thereby reducing local tissue damage and attenuating apoptotic activation.3,19,25 All of these effects would act to protect cells exposed to adverse stimuli, and would also potentially reduce activity in neural pathways associated with pain sensation. Tβ4 has also been shown to regulate cellular actin dynamics and may enhance the cell motility, cell-matrix interactions, and cell-matrix remodeling that occurs during the course of wound healing
This company had a big day yesterday, releasing trial data on a large indication(mucositis). And it is a great example how the manipulation of shorts and MM's can fakeout even the most convicted long.
Make no mistake, like the upcoming dry eye trial here, mucositis was a make or break result for sngx. And what did the trading look like in front of data? Just one look at the chart and you see stock was cut in 1/2; going from over a buck to less than 50 cents. And of course, the message boards was full of conspiracies of leaked data and complete failure. All this on big volume, so very few would buy the wild selloff there.
But, results came and they were very good, and stock recovers.
I dont know how stock here will trade in front of data. But, shorts love to play the game. Lesson here is stay the course, and do not let the corrupt cabal steal your long held shares. And if you really have a pair, put some bids in.
If you go to that worthless site, you will see that Zacks has completely removed their rating on rgrx. I dont know what the whole point of that 1 day downgrade was, but they dont do anything to increase their credibility here.
Now, on to patents, trials, partnerships...................................
Wow, i cant even begin to see any logic to your school of thought. Now we are into the mm's emotional state.?
Its just a bid, inside of yesterday's best.. Its a good thing, and a higher one would be even better,,,,,,,,,,,,,,pretty simple stuff.
OK. but how does a mm being on the bid(meaning he wants to buy stock) somehow imply he is thinking about shorting? Your statement might make a little sense if he was on the offer.
Well, you like to go back and look at all my posts, as you have done many times in the past, so you can find the strong rec if you want. It doesnt fit your agenda so you might not be so inclined, but its there.
And i traded around my position in sngx. I dont feel the need to inform you of my buy/sells there.
Just for fun, its interesting that sngx will have its own binary event in the next couple of days. Huge trial results coming on a very big indication. No position there now. But fun to watch, kinda like what you do here.
You and you ol love interest sno waiting for lower prices. Good to see you 2 making a go of it again. Good luck with lower prices here, market always accomodate slow thinkers.........................
NK is a real small indication. And rgrx got no big response for that first very good data set. There have been other drugs that have shown similar efficacy on a small patient population and it seems that doctors treat it somewhat successfully with off label usage of other drugs. So, NK would be nice but not the E ticket that dry eye is.
No cheering bull. But, many here have bought years ago and have a much larger cost basis. To not add here seems stupid. Price will not get much better than this in front of trial data.
And, selling rgrx whole makes much more sense than trying to get something like the heart indication going. Thats a 100+ million dollar trial. Also, buyer of Korean Rights will want the EU rights; thats the second largest dry eye market in the world. RGRX would have some real cards to play if its a eu pharma and they have already done DD to get Korean rights. Remember what shire payed just for that #$%$ dry eye drug.